molecules-logo

Journal Browser

Journal Browser

Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, and New Hopes, 2nd Edition

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1453

Special Issue Editors


E-Mail Website
Guest Editor
1. Pharmaceutical & Medicinal Chemistry Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine
2. Department of Sciences, University of Basilicata, Via dell’Ateneo Lucano 10, 85100 Potenza, Italy
Interests: design and synthesis of anticancer prodrugs with targeting properties determined by the linker’s type; design and synthesis of prodrugs with inefficient bioavailability; design and synthesis of prodrugs for masking the bitter sensation of commonly used drugs
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, Section of Medicinal Chemistry, School of Medical and Pharmaceutical Sciences, University of Genova, Genova, Italy
Interests: medicinal chemistry; computer-assisted drug design; computational chemistry; ligand–target molecular interactions; GPCRs; CFTR
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genoa, Italy
Interests: medicinal chemistry; drug discovery; heterocyclic compounds; small molecules; anticancer agents; antiviral agents
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following the popularity of the last Special Issue edition, we have produced a second Special Issue version. We are inviting the submission of reviews and original research articles in medicinal chemistry that cover hot topics in the discovery, design, and development of new medicines, such as new agents for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, cancer, and COVID-19, for publication in the Special Issue "Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms."

Furthermore, studies devoted to molecular modeling, molecular dynamics, QSAR, and AI that improve the understanding of drug design and action are encouraged. Articles investigating how a drug's chemical structure impacts its pharmacodynamic and pharmacokinetic features are also welcome. We invite eminent and young academics from around the world to submit papers to this Special Issue.

Prof. Dr. Rafik Karaman
Prof. Dr. Paola Fossa
Dr. Valeria Francesconi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • Alzheimer’s disease
  • anticancer agents
  • schizophrenia
  • molecular modeling
  • molecular dynamics
  • QSAR
  • AI in drug discovery

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 2679 KiB  
Review
Targeting CBP and p300: Emerging Anticancer Agents
by Domiziana Masci, Michela Puxeddu, Romano Silvestri and Giuseppe La Regina
Molecules 2024, 29(19), 4524; https://doi.org/10.3390/molecules29194524 - 24 Sep 2024
Viewed by 1186
Abstract
CBP and p300 are versatile transcriptional co-activators that play essential roles in regulating a wide range of signaling pathways, including Wnt/β-catenin, p53, and HIF-1α. These co-activators influence various cellular processes such as proliferation, differentiation, apoptosis, and response to hypoxia, making them pivotal in [...] Read more.
CBP and p300 are versatile transcriptional co-activators that play essential roles in regulating a wide range of signaling pathways, including Wnt/β-catenin, p53, and HIF-1α. These co-activators influence various cellular processes such as proliferation, differentiation, apoptosis, and response to hypoxia, making them pivotal in normal physiology and disease progression. The Wnt/β-catenin signaling pathway, in particular, is crucial for cellular proliferation, differentiation, tissue homeostasis, and embryogenesis. Aberrant activation of this pathway is often associated with several types of cancer, such as colorectal tumor, prostate cancer, pancreatic and hepatocellular carcinomas. In recent years, significant efforts have been directed toward identifying and developing small molecules as novel anticancer agents capable of specifically inhibiting the interaction between β-catenin and the transcriptional co-activators CBP and p300, which are required for Wnt target gene expression and are consequently involved in the regulation of tumor cell proliferation, migration, and invasion. This review summarizes the most significant and original research articles published from 2010 to date, found by means of a PubMed search, highlighting recent advancements in developing both specific and non-specific inhibitors of CBP/β-catenin and p300/β-catenin interactions. For a more comprehensive view, we have also explored the therapeutic potential of CBP/p300 bromodomain and histone acetyltransferase inhibitors in disrupting the transcriptional activation of genes involved in various signaling pathways related to cancer progression. By focusing on these therapeutic strategies, this review aims to offer a detailed overview of recent approaches in cancer treatment that selectively target CBP and p300, with particular emphasis on their roles in Wnt/β-catenin-driven oncogenesis. Full article
Show Figures

Figure 1

Back to TopTop